Ann: Investor Conference Call, page-43

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 43 Last

Share
Profile

Follow
whytee

17,186 Posts.

2426

09/08/17

21:13

Post #: 26400714
Share

Originally posted by RNClarke ↑

This conference call will be a long winded apology from management.

We are all missing the biggest underlying problem, the algorithms simply do not work. The results posted in the table are excluding the patients who were treated prior and patients with obvious background noise.

A timeline can not be put on how long it will take to retrain these algorithms. There will need to be a further CR to conduct trials, so add another 12 months to your timeline.

Just to put this into perspective, ResApp had a pre-submission meeting in March 2016 clearly outlining the protocols they needed - at every presentation since including ones I attended, management seemed very bullish on their protocols and calibre of hospitals, obtaining the best clinical evidence as possible.

The Australian results might as well not exist. They could have capitalised and had TGA and CE certification approved with the company earning revenue by now. This path of all eggs in the FDA basket has backfired.

It is unbelievable to think the study has been conducted so poorly and that these are the results from the US study. What a sad day.

Expand

Been to the Resapp web site and back through the previous study results. No sign of any study protocols or detailed results, just headline summary presentations showing near perfect accuracy...

Personally I can't help wondering if there were flaws in the preliminary studies design that led to over estimation of accuracy.

RAP Price at posting: 7.0¢ Sentiment: None Disclosure: Not Held
4 Upvote

0 Great analysis

Reply

Top Stories

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

IMU

Imugene kicks off Australian trial for blood cancer treatment

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

HotCopper Highlights: Your most watched and most discussed stocks this week

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive